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Abstract
Sterol biosynthetic pathway is explored for its therapeutic potential for Visceral Leish­
maniasis. In Leishmania, this pathway produces ergosterol which is absent in host and there­
fore is a promising strategy to combat proliferation of both extracellular and intracellular 
forms of the parasite with minimal host toxicity. The present chapter focuses on 3­hydroxy­
3­methylglutaryl­CoA reductase (HMGR) enzyme which is the rate­limiting enzyme of the 
ergosterol biosynthesis. HMGR gene of L. donovani was biochemically and biophysically 
characterized for the first time. HMGR over expressing transgenic parasites were generated 
to evaluate its role in parasite growth and infection ability. A series of statins like atorvas­
tatin, simvastatin and mevastatin were evaluated for its therapeutic efficacy and mode of 
action elucidated. Atorvastatin and mevastatin were found to be killing both the promas­
tigote and amastigote forms of the parasite without exhibiting host cytotoxicity. Besides, 
non-statin class of molecules like resveratrol and glycyrrhizic acid were also analyzed for 
antileishmanial potential. Two antidepressants, ketanserin and mianserin were found to 
kill both L. donovani promastigotes and intracellular amastigotes with no apparent toxicity 
to the host cells. Since targeting of the sterol biosynthetic pathway enzymes may be useful 
therapeutically, the present work may have implications in treatment of Leishmaniasis.
Keywords: Visceral Leishmaniasis, HMGR, ergosterol, statins, antidepressants
1. Introduction
A variety of Leishmania species are reported to cause disease, which afflicts about 12 mil­
lion people in 98 countries of which Indian subcontinent, Sudan and Brazil are the major 
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regions with higher incidence of Leishmaniasis. The World Health Organization (WHO) has 
considered Leishmaniasis to be one of the six priority diseases of its special programme for 
Research and Training in tropical diseases. Visceral Leishmaniasis (VL) being a neglected 
tropical disease has been of concern for several years. Antimonial compounds remain the 
first line drug for VL treatment with amphotericin B and pentamidine being the second line 
drugs. However, both the classes have high toxicity and serious side effects. Drug resistance, 
toxicity and long-term treatment profile are some of the issues which plague the treatment 
regimen. In the wake of this problem, there are increasing efforts to identify vaccine candi­
dates and drug target candidates with equal focus on drug repositioning. Till date, several 
enzymes of various crucial metabolic pathways such as the pentose phosphate pathway, 
trypanothione biosynthesis pathway and sterol biosynthetic pathway have been explored 
in parasites [1]. With the whole genome sequence of Leishmania donovani now available, it 
has become feasible to identify new genes and explore its essentiality in parasite survival 
and host infectivity. Structural analysis of identified enzymes would throw light on poten­
tial active site for designing pharmacophore. Based on this, in silico ligand screening is per­
formed to identify potential compounds from already existing library. This would further 
lead to design and synthesis of new chemical entities whose potency can be evaluated in 
cell­based and target­based screening assays.
Sterol biosynthetic pathway is an important metabolic pathway in fungi and trypanoso­
matids. In recent years, attention has been focused on the sterol metabolism of Leishmania 
as a potential drug target for therapy. In sterol biosynthetic pathway, condensation of two 
acetyl­CoA units leads to formation of acetoacetyl­CoA, followed by the addition of a third 
unit to form 3­hydroxy­3­methylglutaryl­CoA (HMG­CoA), which is further reduced by 
NADPH to produce mevalonic acid. The mevalonate pathway comprises of three steps 
and is catalyzed by acetoacetyl­CoA thiolase, and two mitochondrial enzymes HMG­CoA 
synthase and HMG­CoA reductase, in yeast [2] and in trypanosomatids [3]. Sterols are 
important components of the cell membrane that are important for cellular function and 
maintenance of cell structure. Unlike mammalian cells which have cholesterol as the major 
membrane sterol, trypanosomatids synthesize ergosterol and other 24-methyl sterols that 
are required for their growth and viability. Leishmania parasite contains predominantly 
ergostane-based sterols such as ergosterol, which differ from cholesterol by the presence 
of a 24-methyl group at Δ7 and Δ22 bonds [4]. Therefore, the sterol biosynthetic pathway 
from Leishmania is considered to be an important drug target. Squalene synthase (SQS) 
catalyzes the first committed step of sterol synthesis by coupling two farnesyl molecules to 
form squalene. Two quinuclidine derivatives, ER-119884 and E5700, have been shown to be 
potent antileishmanial and anti­trypanosomal agents. The inhibition of SQS by these com­
pounds decreased endogenous sterol levels of the parasite and caused an anti-proliferative 
effect on the parasite [5]. Sterol 24-C-methyltranferase (SMT) is unique to the parasite and 
validated as a potential drug target against trypanosomatid parasites. Azosterols like keto­
conazole are known to inhibit SMT in fungi. They were also found to be anti-proliferative 
in Leishmania amazonensis [6].
One of the enzymes of the sterol biosynthetic pathway which is focused in this chapter is 
3-hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC:1.1.1.34). HMGR catalyzes the NADPH 
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dependent synthesis of mevalonate from HMG-CoA and is a rate limiting step [7]. There are two 
classes of HMG-CoA reductase: class I (eukaryotic HMGRs) and class II (prokaryotic HMGRs). 
The class I HMGR has an N-terminal membrane domain and is present in eukaryotes and several 
archaea. Class II HMGR lacks this domain and occurs in Pseudomonas mevalonii, Archaeoglobus 
fulgidus, Staphylococcus aureus, Enterococcus faecalis and Streptomycetes [8–11]. L. major HMGR 
enzyme lacks the N-terminal domain and is the only eukaryote with soluble HMGR protein. 
Among kinetoplastids, HMGR has been earlier characterized in L. major and Trypanosoma cruzi 
[12, 13]. Given that ergosterol is an important component of Leishmania membrane, we focused 
our research on identification and validation of HMGR from L. donovani as a potential drug 
target candidate.
L. donovani HMGR gene was identified via a BLAST search of the genome using L. major 
HMGR sequence (www.ebi.ac.uk/parasites/LGN) as the template. LdHMGR gene was 
amplified, cloned in pET30a (+) vector and sequenced (GenBank accession no. JX036280.1). 
LdHMGR exhibited only 25.2% identity (35% similarity) with human HMGR. This signifies 
that host HMGR is significantly different from parasite HMGR. HMGR enzyme is constitu­
tively expressed in Leishmania promastigotes as shown by western blot analysis [14, 27].
1.1. Functional analysis of LdHMGR overexpressors
Next, we were interested to see whether HMGR has any role in parasite growth and infec­
tivity. For this, HMGR was cloned in a Leishmania specific overexpression vector. HMGR 
overexpression in L. donovani promastigotes was confirmed by measuring of HMGR activ­
ity, estimation of ergosterol levels and western blot analysis confirmed the overexpression of 
HMGR gene [15].
1.2. Growth curve analysis of HMGR transfectants
The growth profile of transfected and wild-type parasites in vitro was studied by measuring 
OD at 600 nm of the plated cells for every 24 h. We monitored the growth of parasites and 
LdHMGR transfectants exhibited ~ 1.5 fold increase in growth than compared to wild-type 
and psp vector transfected parasites (Figure 1A).
1.3. Role of HMGR in parasite infection ability
The transfectants were tested for their ability to infect THP-1 differentiated macrophages. The 
stationary phase of wild-type and HMGR overexpressing promastigotes were used to infect 
THP-1 differentiated macrophages. The percentage of infection with wild type was consid­
ered as 100% and relatively percentage of infection was calculated for psp and HMGR over­
expressors. The HMGR transfectants exhibited ~2 fold change in the infectivity compared to 
wild­type parasites (Figure 1B).
In other organisms like yeast, it was reported that combined overexpression of genes 
(ERG1 and ERG11) leads to significant increase in the amount of total sterols by threefold in 
comparison with a wild­type strain in yeast. The HMG­CoA reductase controls the entering 
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of intermediates on the pre-squalene part of the pathway and Erg1p and Erg11p seem to 
control the transfer of intermediates into the post­squalene part of sterol biosynthetic path­
way [16]. Other studies reported that overexpression of HMGR in yeast leads to increased 
linalool production which is a plant monoterpene which display antiparasitic, antimicrobial 
and antiviral properties as well as a plethora of promising health benefits [17].
2. HMGR inhibition profiles
2.1. Evaluation of antileishmanial effect of class I statin (simvastatin), class II statin 
(atorvastatin) and mevastatin
The inhibitors used in the present study were atorvastatin, simvastatin and mevastatin. The 
concentrations of atorvastatin and mevastatin at which 50% growth of L. donovani promas­
tigotes was inhibited (IC50) were 19.4 ± 3.07 μM and 23.8 ± 4.2 μM respectively [14, 18, 25]. 
The IC50 value of simvastatin was 73.2 ± 3.7 μM and at 100 μM it caused only 63% inhibition. The cytotoxicity of atorvastatin, simvastatin and mevastatin against THP-1 differentiated 
macrophages was determined by using MTT assay. The IC50 value of three drugs were found to be above 100 μM, that is, noncytotoxic to host macrophage cell line. Miltefosine inhib­
ited promastigote growth with an IC50 value of 14.6 μM. Atorvastatin was found to inhibit 
L.  donovani promastigotes at low micromolar concentrations compared to mevastatin and 
simvastatin. The concentrations of atorvastatin, simvastatin and mevastatin at which 50% 
growth of L. donovani amastigotes was inhibited (IC50) were 6.75 ± 0.353 μM, 21.5 ± 4.94 μM and 7.5 ± 1.1 μM respectively. The amastigotes were approximately threefold more sensitive 
to atorvastatin and resveratrol than promastigotes. Miltefosine was taken as the reference 
drug, and its IC50 value for amastigotes was 3.9 ± 1.27 [14, 25]. The IC50 values are depicted 
in Table 1.
The inhibitors were screened for their ability to inhibit the catalytic efficiency of recombinant 
LdHMGR. The IC50 value of atorvastatin, simvastatin and mevastatin was found to be half maximal at around 315 ± 2.12 nM, 43.66 ± 31.5 μM and 42.2 ± 3.0 μM respectively. Atorvastatin 
(1 μM) resulted in 93.5 ± 7.2% inhibition of the recombinant HMGR. Table 1 shows the IC50 values of the statins on recombinant HMGR.
Figure 1. Functional analysis of LdHMGR overexpressors. (A) Growth analysis of wild-type (WT), psp and LdHMGR 
overexpressing parasites; (B) evaluation of infection efficiency of wild-type (WT), psp and LdHMGR overexpressors. 
Data were expressed as mean ± standard deviations from three independent experiments. *p ≤ 0.05.
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2.2. Evaluation of antidepressants as HMGR inhibitors
Tricyclic drugs, antidepressants and antipsychotics are reported to be toxic to both the promas­
tigote and amastigote forms of Leishmania [19]. Imipramine, a tricyclic antidepressant belonging 
to the same class of cationic amphiphilic drugs, when administered orally was found to be active 
against both antimony-sensitive and antimony resistant clinical isolates of L. donovani [20].
Ketanserin is a serotonin S2-receptor antagonist which is used as an antihypertensive agent. 
The IC50 value of ketanserin for L. donovani promastigotes was 37.8 μM and intracellular amas­tigotes was 28.5 μM. It was however found to be noncytotoxic up to a concentration of 100 μM, 
when tested on differentiated THP-1 cells. Miltefosine inhibited amastigote growth with an 
IC50 value of 3.4 μM which correlated with the previously reported data [21]. However, the standard drug killed the macrophage cells at an IC50 value of 43.6 μM. This was well corre­lated with the already published results on the effect of miltefosine on THP-1 and J774A.1 cell 
line [22, 23]. These results showed that ketanserin displayed antileishmanial activity at non­
cytotoxic concentrations. We evaluated the effect of ketanserin on recombinant LdHMGR and 
found its IC50 value to be 43 ± 2.5 μM. This data showed that ketanserin binds to the LdHMGR enzyme active site and inhibits its activity (Table 2) [15].
Mianserin hydrochloride is a noradrenergic and specific serotonergic antidepressant (NaSSA) 
with a tetracyclic structure and is used for the treatment of depressive illness and depres­
sion associated with anxiety [24]. Mianserin strongly blocks postsynaptic 5-HT2 receptors 
and only weakly blocks post synaptic 5-HT1 and 5-HT3 receptors and blocks moderately 
presynaptic α2 receptors [24]. The effect of mianserin was investigated on the proliferation 
rate of L. donovani promastigotes and amastigotes. The dose-dependent antileishmanial effect 
of mianserin against L. donovani promastigotes resulted in significant reduction in viable para­
sites compared to the untreated parasites. The concentration of mianserin at which 50% of 
the promastigote and amastigote growth was inhibited was 21 ± 3.7 μM and 46.4 ± 5.2 μM 
respectively. Mianserin up to 100 μM failed to cause any toxic effect on viability of THP-1 
differentiated macrophages indicating that mianserin selectively inhibits Leishmania promas­














Atorvastatina 19.4 ± 3.07 6.75 ± 0.353 >100 >14.8 0.315 ± 2.12
Simvastatina 73.2 ± 3.7 21.5 ± 4.94 >100 >4.65 43.66 ± 31.5
Mevastatina 23.8 ± 4.2 7.5 ± 1.1 >100 >13.3 42.2 ± 3.0
Miltefosineb 14.6 ± 1.7 3.9 ± 1.27 43.6 ± 5.5 11.17 —
aDinesh et al. [14, 25].
bDinesh et al. [18].
Table 1. Antileishmanial effect of statins.
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3. Natural products as inhibitors of HMGR
The inhibitors used in the present study were resveratrol and glycyrrhizic acid. The concen­
trations of resveratrol at which 50% growth of L. donovani promastigotes was inhibited (IC50) was 36.1 ± 3.6 μM. The cytotoxicity of resveratrol against THP-1 differentiated macrophages 
was determined by using MTT assay. The results showed the IC50 value of three drugs was found to be above 100 μM, that is, noncytotoxic to host macrophage cell line. The concentra­
tions of resveratrol at which 50% growth of L. donovani amastigotes was inhibited IC50 value was 9.5 ± 2.12 μM [14, 25]. The data are depicted in Table 3.
Glycyrrhiza glabra, which is popularly known as liquorice is used for the treatment of pul­
monary diseases and inflammatory processes [26]. Glycyrrhizic acid (GA), licochalone A 
and Glycyrrhetinic acid which have been reported to exert antileishmanial properties are the 
major bioactive components in liquorice root [27, 29, 30]. GA exhibits potent antileishmanial 
and immunomodulatory properties with enhanced parasite clearance [27]. A dose­dependent 
inhibition of the viability of L. donovani promastigotes was observed in the presence of GA. The 
IC50 determined from the graph was approximately 34 ± 2.9 μM. GA was found to inhibit intra­













Glycyrrhizic acida 34.0 ± 2.9 20.0 ± 4.24 >100 >5.0 24.0 ± 4.3
Resveratrolb 36.1 ± 3.6 9.5 ± 2.12 >100 >10.5 46.3 ± 16.4
Miltefosinea 15.3 ± 2.1 3.8 ± 1.2 44.2 ± 5.29 11.5 —
aDinesh et al. [28].
bDinesh et al. [14, 25].













Mianserina 21.0 ± 3.7 46.4 ± 5.2 >100 >2.15 19.8 ± 3.1
Ketanserinb 37.8 ± 3.3 28.5 ± 1.9 >100 >3.5 43.0 ± 2.5
Miltefosinea 14.6 ± 1.7 3.4 ± 0.9 43.6 ± 5.5 12.8 —
aDinesh et al. [14, 25].
bSingh et al. [15].
Table 2. Antileishmanial effect of antidepressants.
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to 100 μM concentration. GA was tested against recombinant LdHMGR enzyme at the range of 
10–100 μM concentration. The IC50 value was found to be 24 ± 4.3 μM (Table 3).
In Leishmania sterol, biosynthetic pathway produces ergosterol which is absent in host. This 
makes LdHMGR enzyme a potential drug target for designing parasite specific molecules. 
The present review encompasses functional characterization of L. donovani HMGR enzyme 
and the evaluation of the effect of various HMGR inhibitors as potential candidates for treat­
ment of Leishmaniasis. Inhibitors which showed inhibition of both the extracellular and intra­
cellular forms of the parasites at low micromolar range with no cytotoxicity to host cells are 
promising antileishmanial candidates. They can be further explored in an experimental ani­
mal model of VL to evaluate its anti-VL efficacy.
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